Literature DB >> 9395190

Telomere length in myelodysplastic syndromes.

J Boultwood1, C Fidler, R Kusec, K Rack, P J Elliott, O Atoyebi, R Chapman, D G Oscier, J S Wainscoat.   

Abstract

We have studied telomere length in the bone marrow cells or the granulocyte and lymphocyte cell fractions of 54 patients with myelodysplastic syndromes (MDS) by Southern blot hybridization using the (TTAGGG)4 probe. The average telomere length expressed as the peak telomere repeat array (TRA) in the peripheral blood, or bone marrow samples obtained from a group of 21 healthy age-matched controls (26-89 years old, mean age 55), ranged between 7.5 and 9.5 kb (mean peak TRA 8.6 kb). Twenty-four patients with refractory anemia (RA) were studied; 10/24 (42%) had telomere reduction (<7.5 kb) relative to age-matched controls and the mean peak TRA was 7.5 kb (range 4.0-9.0 kb). Eleven patients with RA with excess blasts (RAEB) were studied; 5/11 (45%) had reduced telomeres relative to age-matched controls and the mean peak TRA was 7.1 kb (range 5.0-9.0 kb). Eighteen patients with MDS in transformation to AML, comprising 15 with RAEB in transformation (RAEBt) and 3 with CMML in transformation (CMMLt), were also studied. Thirteen of eighteen patients (72%) had telomere reduction relative to age-matched controls and the mean peak TRA was 6.1 kb (range 3.5-9.0 kb). Thirty-six patients included in the study had either a normal karyotype or a simple karyotype (1 karyotypic change) and 20/36 (55%) of these had telomere reduction and the mean peak TRA was 7.1 kb (range 4.3-9.0 kb); 8 patients had a complex karyotype (3 or more karyotypic changes) and 5/8 (62%) of these had telomere reduction and the mean peak TRA was 6.1 kb (range 3.5-9.0 kb). We conclude, firstly that there is heterogeneity of telomere length in MDS and that this is observed throughout the spectrum of FAB-subtypes. Secondly, these data show that a marked reduction in telomere length in MDS if often associated with leukemic transformation and with the presence of complex karyotypic abnormalities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395190     DOI: 10.1002/(sici)1096-8652(199712)56:4<266::aid-ajh12>3.0.co;2-7

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  19 in total

1.  Establishment of novel human esophageal cancer cell line in relation to telomere dynamics and telomerase activity.

Authors:  Y Kiyozuka; A Asai; D Yamamoto; H Senzaki; S Yoshioka; H Takahashi; K Hioki; A Tsubura
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

2.  Telomere length in myelodysplastic syndromes.

Authors:  Dana E Rollison; P K Epling-Burnette; Jong Y Park; Ji-Hyun Lee; Hyun Park; Kristen Jonathan; Ashley L Cole; Jeffrey S Painter; Mayenha Guerrier; Johana Meléndez-Santiago; William Fulp; Rami Komrokji; Jeffrey Lancet; Alan F List
Journal:  Leuk Lymphoma       Date:  2011-06-03

Review 3.  Fanconi anaemia.

Authors:  M D Tischkowitz; S V Hodgson
Journal:  J Med Genet       Date:  2003-01       Impact factor: 6.318

Review 4.  Telomere biology in hematopoiesis and stem cell transplantation.

Authors:  Shahinaz M Gadalla; Sharon A Savage
Journal:  Blood Rev       Date:  2011-07-20       Impact factor: 8.250

5.  Telomere length and anaemia in old age: results from the Newcastle 85-plus Study and the Leiden 85-plus Study.

Authors:  Wendy P J Den Elzen; Carmen Martin-Ruiz; Thomas von Zglinicki; Rudi G J Westendorp; Thomas B L Kirkwood; Jacobijn Gussekloo
Journal:  Age Ageing       Date:  2011-05-27       Impact factor: 10.668

Review 6.  Chromosome and molecular abnormalities in myelodysplastic syndromes.

Authors:  Pierre Fenaux
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

7.  Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS.

Authors:  A Mario Marcondes; Aravind Ramakrishnan; H Joachim Deeg
Journal:  Curr Cancer Ther Rev       Date:  2009-11-01

8.  p16(INK4a) protects against dysfunctional telomere-induced ATR-dependent DNA damage responses.

Authors:  Yang Wang; Norman Sharpless; Sandy Chang
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

9.  No telomere shortening in marrow stroma from patients with MDS.

Authors:  A Mario Marcondes; Steven Bair; Peter S Rabinovitch; Ted Gooley; H Joachim Deeg; Rosana Risques
Journal:  Ann Hematol       Date:  2008-12-03       Impact factor: 3.673

10.  Telomerase dysfunction and dyskeratosis congenita.

Authors:  Amanda J Walne; Inderjeet Dokal
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.